PT2385: Clinical Trials

2 trials of PT2385, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Completed 1

Follow PT2385: new trials by email Literature Review of PT2385 trials Research Report on PT2385

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers
PT2385 - Healthy
Phase 1CompletedPeloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)162015-09-012015-12-10
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
MK-3795, Nivolumab, Cabozantinib - ccRCC, RCC
Phase 1Active not recruitingPeloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1102014-11-252024-06-17

Conditions studied

Carcinoma, Renal Cell (1)  ·  Kidney Neoplasms (1)

Sponsors

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)

Countries

United States (2)

Results publications

PMID 29257710